非酒精性脂肪肝并发肝纤维化患者应用血滞通胶囊配合阿托伐他汀钙片治疗的临床观察  

Clinical Observation of Xuezhitong Capsules Combined with Atorvastatin Calcium Tablets in the Treatment of Patients with Non-alcoholic Fatty Liver Disease and Hepatic Fibrosis

作　　者：徐玉珍 钱翔 轸微 陈丽娟 XU Yuzhen;QIAN Xiang;ZHEN Wei;CHEN Lijuan(Shangrao Municipal Hospital,Jiangxi Province,Shangrao 334000,China;不详)

机构地区：[1]江西省上饶市立医院,江西上饶334000

出　　处：《中国医学创新》2022年第25期48-52,共5页Medical Innovation of China

基　　金：江西省卫健委科技计划项目(202212803)。

摘　　要：目的:探讨非酒精性脂肪肝(NAFLD)并发肝纤维化患者应用血滞通胶囊配合阿托伐他汀钙片的治疗效果。方法:选取2020年1月-2021年5月于上饶市立医院诊治的66例NAFLD并发肝纤维化患者。采用随机数字表法分为对照组与观察组,各33例。对照组予以阿托伐他汀钙片治疗,观察组基于对照组予以血滞通胶囊,两组均持续治疗3个月。比较两组临床疗效。比较治疗前后两组肝纤维化指标[层粘连蛋白(LN)、血清Ⅳ型胶原蛋白(Ⅳ-C)、血清Ⅲ型前胶原氨端肽(PcⅢ)、透明质酸(HA)]、血脂指标[低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)]、肝功能指标[谷草转氨酶(AST)、谷氨酥转肽酶(GGT)、谷丙转氨酶(ALT)]。比较两组便秘、恶心呕吐、头痛、皮疹等不良反应发生率。结果:治疗3个月后,观察组总有效率为96.97%,高于对照组的78.79%,差异有统计学意义(P<0.05);治疗前,两组肝纤维化指标、血脂指标、肝功能指标比较,差异均无统计学意义(P>0.05),治疗3个月后,观察组LN、Ⅳ-C、PcⅢ、HA、LDL-C、TG、TC、AST、GGT、ALT均低于对照组,HDL-C高于对照组,差异均有统计学意义(P<0.05);治疗3个月后,观察组不良反应发生率为6.06%,低于对照组的18.18%,但差异无统计学意义(P>0.05)。结论:对NAFLD并发肝纤维化患者予以血滞通胶囊配合阿托伐他汀钙片具有较好疗效,具有抗肝纤维化,调节血脂水平,改善肝功能作用,且安全性较好。Objective:To investigate the therapeutic effect of Xuezhitong Capsules combined with Atorvastatin Calcium Tablets on patients with non-alcoholic fatty liver disease(NAFLD)and hepatic fibrosis.Method:A total of 66 patients with NAFLD and hepatic fibrosis who were admitted to Shangrao Municipal Hospital from January 2020 to May 2021 were selected.They were divided into control group and observation group by random number table method,33 cases in each group.The control group were treated with Atorvastatin Calcium Tablets,and the observation group were treated with Xuezhitong Capsules based on the treatment of the control group.Both groups were given 3 months of continuous treatment.Clinical effects in the two groups were compared.Hepatic fibrosis indicators[laminin(LN),serum typeⅣcollagen(Ⅳ-C),serum typeⅢprocollagen(PcⅢ),hyaluronic acid(HA)],blood lipid indicators[low density lipoprotein cholesterol(LDL-C),triacylglycerol(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C)]and liver function indicators[aspartate aminotransferase(AST),gamma-glutamyl transferase(GGT),alanine aminotransferase(ALT)]in the two groups were compared before and after treatment.The incidence rates of adverse reactions such as constipation,nausea and vomiting,headache and skin rash were compared between the two groups.Result:After 3 months of treatment,the total effect rate of observation group was 96.97%higher than 78.79%of control group(P<0.05).There was no statistically significant difference in hepatic fibrosis indicators,blood lipids and liver function indicators between the two groups before treatment(P>0.05).After 3 months of treatment,the levels of LN,Ⅳ-C,PcⅢ,HA,LDL-C,TG,TC,AST,GGT and ALT in the observation group were lower than those in the control group,and the level of HDL-C was higher than that in control group(P<0.05).After 3 months of treatment,the incidence of adverse reactions in observation group was 6.06%lower than 18.18%in control group,but there was no significant difference(P>0.05).Conclusio

关 键 词：非酒精性脂肪肝 肝纤维化 阿托伐他汀钙片 血滞通胶囊 

分 类 号：R575.5[医药卫生—消化系统] R575.2[医药卫生—内科学]